KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $9.3 billion.

  • Royalty Pharma's Total Non-Current Liabilities rose 1855.18% to $9.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.3 billion, marking a year-over-year increase of 1855.18%. This contributed to the annual value of $9.3 billion for FY2025, which is 1855.18% up from last year.
  • Per Royalty Pharma's latest filing, its Total Non-Current Liabilities stood at $9.3 billion for Q4 2025, which was up 1855.18% from $9.2 billion recorded in Q3 2025.
  • Royalty Pharma's 5-year Total Non-Current Liabilities high stood at $9.3 billion for Q4 2025, and its period low was $6.3 billion during Q3 2023.
  • In the last 5 years, Royalty Pharma's Total Non-Current Liabilities had a median value of $7.3 billion in 2022 and averaged $7.5 billion.
  • Per our database at Business Quant, Royalty Pharma's Total Non-Current Liabilities tumbled by 1362.32% in 2023 and then soared by 2495.94% in 2024.
  • Royalty Pharma's Total Non-Current Liabilities (Quarter) stood at $7.3 billion in 2021, then increased by 0.25% to $7.3 billion in 2022, then fell by 13.57% to $6.3 billion in 2023, then rose by 24.96% to $7.9 billion in 2024, then increased by 18.55% to $9.3 billion in 2025.
  • Its last three reported values are $9.3 billion in Q4 2025, $9.2 billion for Q3 2025, and $8.4 billion during Q2 2025.